Education
About Us
Working with TipRanks
Follow Us
Neuphoria Therapeutics Inc. (NEUP)
:NEUP
RESEARCH TOOLSreports
Total Valuation
Neuphoria Therapeutics has a market cap or net worth of $13.54M. The enterprise value is -$3.34M.
Market Cap$13.54M
Enterprise Value-$3.34M
Share Statistics
Neuphoria Therapeutics has 1,879,962 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,879,962
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Neuphoria Therapeutics’s return on equity (ROE) is -0.89 and return on invested capital (ROIC) is -74.21%.
Return on Equity (ROE)-0.89
Return on Assets (ROA)-0.56
Return on Invested Capital (ROIC)-74.21%
Return on Capital Employed (ROCE)-0.75
Revenue Per Employee0.00
Profits Per Employee-1.94M
Employee Count8
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Neuphoria Therapeutics is -80.06. Neuphoria Therapeutics’s PEG ratio is 2.32.
PE Ratio-80.06
PS Ratio0.00
PB Ratio64.81
Price to Fair Value70.92
Price to FCF32.45
Price to Operating Cash Flow2.59K
PEG Ratio2.32
Income Statement
In the last 12 months, Neuphoria Therapeutics had revenue of 0.00 and earned -15.49M in profits. Earnings per share was -0.10.
Revenue0.00
Gross Profit0.00
Operating Income-17.89M
Pretax Income-15.58M
Net Income-15.49M
EBITDA-17.13M
Earnings Per Share (EPS)-0.10
Cash Flow
In the last 12 months, operating cash flow was 3.66M and capital expenditures 0.00, giving a free cash flow of 3.43M billion.
Operating Cash Flow3.66M
Free Cash Flow3.43M
Free Cash Flow per Share1.82
Dividends & Yields
Neuphoria Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.75
52-Week Price Change-5.93%
50-Day Moving Average6.26
200-Day Moving Average4.84
Relative Strength Index (RSI)66.47
Average Volume (3m)30.51K
Important Dates
Neuphoria Therapeutics upcoming earnings date is Feb 20, 2025, TBA (Confirmed).
Last Earnings DateAug 21, 2024
Next Earnings DateFeb 20, 2025
Ex-Dividend Date―
Financial Position
Neuphoria Therapeutics as a current ratio of 3.45, with Debt / Equity ratio of 0.66%
Current Ratio3.45
Quick Ratio3.45
Debt to Market Cap<0.01
Net Debt to EBITDA0.72
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Neuphoria Therapeutics has paid -87.32K in taxes.
Income Tax-87.32K
Effective Tax Rate<0.01
Enterprise Valuation
Neuphoria Therapeutics EV to EBITDA ratio is -71.67, with an EV/FCF ratio of -83.65.
EV to Sales0.00
EV to EBITDA-71.67
EV to Free Cash Flow-83.65
EV to Operating Cash Flow-83.65
Balance Sheet
Neuphoria Therapeutics has $17.05M in cash and marketable securities with AU$172.46K in debt, giving a net cash position of -$16.87M billion.
Cash & Marketable Securities$17.05M
Total DebtAU$172.46K
Net Cash-$16.87M
Net Cash Per Share-$8.97
Tangible Book Value Per Share$0.02
Margins
Gross margin is 96.83%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin96.83%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Neuphoria Therapeutics is $21.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$21.00
Price Target Upside181.50% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―